Here are 11 updates on GI companies from the past week:
Takeda and BioSurfaces entered into a joint research program aimed at developing new medical devices for gastrointestinal diseases.
Eisai submitted applications to the FDA and European Medicine Agency for its liver cancer drug lenvatinib mesylate.
Midatech Pharma completed the preclinical program for its wholly-owned, advanced liver cancer candidate MTD119.
Bristol-Myers Squibb reported second quarter fiscal year 2017 revenues of $5.1 billion on July 27.
Exact Sciences is deciding between Madison, Wis., and Fitchburg, Wis., for a possible expansion.
Fujifilm launched the ClutchCutter and FlushKnife devices on July 27.
Boston Scientific reported second quarter fiscal year 2017 sales of $2.25 billion on July 27.
Cantel Medical Corp. is acquiring BHT Hygienetechnik Holding GmbH for $60.8 million on a debt-free basis.
The FDA approved Bristol-Myers Squibb's Opdivo for use in adults and in pediatric patients 12 years old and older.
Lumendi received ISO 13485 certification from BSI America, a medical device testing and certification company, for its medical devices.